Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | PRF1 | P14222 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9192828 | 0.82 | ALDH1A1 (0.50) | ALDH1A1ADRA1DADRA1AADRA1BDPP4 | |
| SCHEMBL9900205 | 0.74 | ADRA1D (0.43) | ALDH1A1ADRA1DADRA1AADRA1BDPP4 | |
| SCHEMBL15898183 | 0.74 | ALDH1A1 (0.42) | ALDH1A1ADRA1DADRA1AADRA1BDPP4 | |
| SCHEMBL16901827 | 0.71 | ALDH1A1 (0.47) | ALDH1A1ADRA1DADRA1AADRA1BDPP4 | |
| SCHEMBL158329 | 0.71 | — | — | |
| SCHEMBL29020313 | 0.71 | ALDH1A1 (0.44) | ALDH1A1ADRA1DADRA1AADRA1BDPP4 | |
| SCHEMBL16903660 | 0.69 | ADRA1D (0.40) | ALDH1A1ADRA1DADRA1AADRA1B | |
| SCHEMBL1432890 | 0.69 | ACACA (0.41) | ALDH1A1ADRA1DADRA1AADRA1B | |
| SCHEMBL1418985 | 0.68 | ALDH1A1 (0.47) | ALDH1A1ADRA1DADRA1AADRA1BDPP4 | |
| SCHEMBL27982838 | 0.68 | ALDH1A1 (0.47) | ALDH1A1ADRA1DADRA1AADRA1BDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160257697-A1 | THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OFUSE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257697-A1 | THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OFUSE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-09-08 | — | — | US | disclosed |
| WO-2014110706-A1 | THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257697-A1 | THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OFUSE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, TPMT, RPL35 | ALDH1A1 301/4885ADRA1D 3069/4885ADRA1A 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.